Association of vitamin D and platelet-to-lymphocyte ratio in treatment escalation risk for newly diagnosed Crohn’s disease adults

Table 4 Interaction between platelet-to-lymphocyte ratio and baseline VD levels on Infliximab and/or immunosuppressants usage in newly diagnosed CD patients

VD deficiency	n	person- months	Events	Crude model		Adjusted model*
VD deficiency	n	person- months	(%)	HR (95% CI)	P	HR (95% CI)	P
Platelet-to-lymphocyte ratio < Q1
Q1	2	6	1 (50.0)	Ref	—	Ref	—
Q2	5	19	0 (0)	ns	ns	ns	ns
Q3	10	40	4 (40.0)	0.89 (0.10–8.03)	0.915	ns	ns
Q4	5	46	1 (20.0)	0.33 (0.02–5.35)	0.432	ns	ns
Platelet-to-lymphocyte ratio ≥ Q1
Q1	25	82	16 (64.0)	Ref	—	Ref	—
Q2	23	59	15 (65.2)	1.39 (0.68–2.82)	0.364	0.56 (0.17–1.81)	0.332
Q3	16	140	8 (50.0)	0.42 (0.17–1.01)	0.053	0.41 (0.10–1.66)	0.214
Q4	22	89	9 (40.9)	0.57 (0.25–1.30)	0.180	0.18 (0.05–0.62)	0.006
				P for trend = 0.045		P for trend = 0.014
				P^a_interaction = 0.750		P^a_interaction = 0.039

*Adjusted for age of onset, sex, region, smoking, season of vitamin D measurement, disease location, disease behavior, occupation, BMI, CDAI, EIM and history of perianal surgery
^aP value of the interaction between platelet-to-lymphocyte ratio and quartiles of VD levels
ns: non-significant

ISSN: 1475-2891